dm+d

Unassigned

New Medicines

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have failed or are ineligible for HSCT

Information

New molecular entity
AbbVie
AbbVie

Development and Regulatory status

Phase II Clinical Trials
Phase III Clinical Trials
Phase II Clinical Trials

Category

A humanised immunoglobulin 1 (IgG1) bispecific antibody that binds specifically to the antigens CD20 and CD3.
The overall annual incidence of DLBCL in Europe is 3.8 per 100,000 but the incidence increases with age and varies considerably across Europe [1].
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who have failed or are ineligible for HSCT
Subcutaneous injection